ALTERITY THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 AUD | 0.00% |
|
0.00% | -28.57% |
Presenter SpeechRosemary Cummins (Analysts)Well, good morning. Good morning for the Australian...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Companyâs lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinsonâs disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Calendar
2025-02-26
- Q2 2025 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.57% | 17.53M | |
| +29.36% | 49.46B | |
| +0.74% | 42.58B | |
| +48.88% | 42.49B | |
| -5.26% | 29.09B | |
| +12.44% | 26.61B | |
| -24.19% | 18.64B | |
| +7.29% | 13.16B | |
| +31.96% | 12.55B | |
| +23.78% | 12.1B |
- Stock Market
- Equities
- ATH Stock
- News Alterity Therapeutics Limited
- Transcript : Alterity Therapeutics Limited - Special Call
